Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
Schizophrenia, Schizoaffective Disorder, Tardive Dyskinesia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring negative symptoms schizophrenia, Atypical antipsychotics, Neurocognition impairment, obesity risk factor, Diabetes insulin resistance schizophrenia
Eligibility Criteria
Inclusion Criteria:
- Male or female
- age 18-65 years
- DSM-IV diagnosis of Schizophrenia
- SANS score greater than 30
Exclusion Criteria:
- Current (past 12 months) substance use disorder
- Except nicotine dependence
- Major medical disorders : hematological disorder
- Chronic active hepatitis, acute hepatitis, cirrhosis of liver, AIDS
- Pregnancy and breast-feeding
- Neurological disorders including epilepsy
- traumatic brain injury
- HAM-D score greater than 24
Sites / Locations
- Queen's University
- Regional Mental Health Care London
- Northern Ontario Medical School
- Northwick Park Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Ginsana-115
Sugar Pill
Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily